<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00651235</url>
  </required_header>
  <id_info>
    <org_study_id>200610030M</org_study_id>
    <nct_id>NCT00651235</nct_id>
  </id_info>
  <brief_title>A Randomized, Open-label, LOSARTAN Therapy on the Progression of Aortic Root Dilation in Patients With Marfan Syndrome</brief_title>
  <acronym>MFS</acronym>
  <official_title>A Randomized, Open-label, Active Control Trial to Evaluate the Effect of LOSARTAN Therapy on the Progression of Aortic Root Dilation in Patients With Marfan Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Taiwan University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Taiwan University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the efficacy of angiotensin II receptor blocker, Losartan, to prevent progressive
      dilation of aortic root in patients with Marfan syndrome.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Marfan syndrome (MFS) is a multisystem connective tissue disorder of autosomal dominant
      inheritance1. The cardinal features are noted in the cardiovascular, ocular, and skeletal
      system. The most life-threatening complication of MFS is progressive aortic root dilation
      leading to aortic dissection or rupture. Losartan, an angiotensin II type I receptor (AT1)
      antagonist, is a drug already in clinical use for hypertension and type II diabetic
      nephropathy. A recent study showed that Losartan prevents aortic root dilation and lung
      problem in a mouse model of MFS. Therefore, the goals of this clinical trial are to examine
      the efficacy and safety of Losartan in patients with Marfan syndrome for aortic root dilation
      prevention.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>February 2007</start_date>
  <completion_date type="Anticipated">June 2011</completion_date>
  <primary_completion_date type="Anticipated">February 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Echocardiograms</measure>
    <time_frame>4 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">44</enrollment>
  <condition>Marfan Syndrome</condition>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In combination therapy,the maximal dose of Losartan is 100 mg/day for adult and 50 mg/day for children. 50 mg of Atenolol once daily, 20 mg of Propranolol twice daily for adult and 1 mg/Kg/day for children</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The maximal dose of Atenolol or Propranolol is 150 mg/day for adult and 2 mg/Kg/day for children.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Losartan and Atenolol or Propranolol</intervention_name>
    <description>50 mg of Atenolol once daily, 20 mg of Propranolol twice daily for adult and 1 mg/Kg/day for children.
Losartan is 100 mg/day for adult and 50 mg/day for children.</description>
    <arm_group_label>B</arm_group_label>
    <other_name>Cozaar and Tenormin or Inderal</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atenolol or Propranolol</intervention_name>
    <description>The maximal dose of Atenolol or Propranolol is 150 mg/day for adult and 2 mg/Kg/day for children.</description>
    <arm_group_label>A</arm_group_label>
    <other_name>Tenormin or Inderal</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria

          -  Marfan syndrome with recognized aortic root dilation

          -  Patients must be older than one year of age

          -  Beta-blocker treatment at least three months

          -  Must sign an informed consent form

        Exclusion criteria

          -  Prior to aortic root surgery

          -  Aortic root dimension more than 5.5cm

          -  Aortic surgery within 6 months

          -  Diabetes mellitus or liver and renal dysfunction or asthma

          -  Pregnancy

          -  Intolerance to Losartan therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mei-Hwan Wu</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Taiwan University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hsin-Hui Chiou</last_name>
    <phone>886-2-2312-3456</phone>
    <phone_ext>3160</phone_ext>
    <email>eliachiou@yahoo.com.tw</email>
  </overall_contact>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>June 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 3, 2008</study_first_submitted>
  <study_first_submitted_qc>April 1, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 2, 2008</study_first_posted>
  <last_update_submitted>June 8, 2010</last_update_submitted>
  <last_update_submitted_qc>June 8, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 9, 2010</last_update_posted>
  <responsible_party>
    <name_title>Mei -Hwan Wu</name_title>
    <organization>National Taiwan University Hospital</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Marfan Syndrome</mesh_term>
    <mesh_term>Arachnodactyly</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Losartan</mesh_term>
    <mesh_term>Propranolol</mesh_term>
    <mesh_term>Atenolol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

